Speaker Companion Guide

Anxiety Management in Outpatient Psychiatry: Evidence-Based Pharmacotherapy and Psychotherapy

Presenter Introduction

How to Use This Guide

This companion guide is designed to support your delivery of the CME presentation on anxiety management. It contains:

Presentation Timing Options

Format Duration Strategy
60-Minute Session 55 min content + 5 min Q&A Focus on slides 1-5, 9-13, 16, 20, 23. Condense pharmacotherapy tables; skip detailed neurobiology.
90-Minute Session 75 min content + 15 min Q&A Full presentation including all slides, with extended case discussion and interactive polling on slides 9, 13, 16.

Audience Level Calibration

👨‍⚕️ Primary Care Audience
  • Emphasize screening and identification
  • Focus on first-line treatments only
  • Stress when to refer to psychiatry
  • Highlight medication interactions
  • Provide clear documentation templates
🧠 Psychiatry Audience
  • Emphasize treatment-resistant strategies
  • Dive deeper into neurobiology
  • Discuss augmentation approaches
  • Compare CBT protocols in detail
  • Include more case complexity

Technology Checklist

Talking Points Per Slide

01 Title Slide

  • Welcome and Hook: "Anxiety disorders affect 1 in 5 adults—and they're among the most treatable psychiatric conditions we see. Yet they often go undiagnosed for years."
  • Preview: Today we'll cover evidence-based approaches to diagnosis, pharmacotherapy, and psychotherapy that you can implement immediately.
  • Set Expectations: Interactive discussion encouraged; case examples throughout; handout materials for reference.
"Let's begin by understanding just how common these conditions are in our practices..."

02 CME Learning Objectives

  • Review objectives briefly—don't just read them.
  • Emphasize practical application: "These aren't abstract goals—each one translates directly to clinical decisions you'll make this week."
  • Common misconception: Some providers still believe anxiety is 'just stress' or that SSRIs don't work for physical symptoms—both are false.
"Now let's ground these objectives in the data..."

03 Epidemiology

  • Key stat: Anxiety disorders are THE most common psychiatric condition—more common than depression.
  • Point out economic burden: $42 billion—this isn't just patient suffering, it's system costs too.
  • Emphasize comorbidity: 60% have comorbid conditions—rarely pure anxiety in practice.
  • Common misconception: Specific phobias are most common but often not impairing enough to seek treatment.
Memorize: 18.1% lifetime prevalence—nearly 1 in 5 adults.
"Given this prevalence, accurate diagnosis becomes critical..."

04 DSM-5 Anxiety Disorder Overview

  • Key distinction: Duration criteria are crucial—GAD and SAD require 6 months; panic requires 1 month of anticipatory anxiety.
  • Note on comorbidity: These categories aren't mutually exclusive—patients often meet criteria for multiple disorders.
  • Common misconception: OCD and PTSD are NOT classified as anxiety disorders in DSM-5—they have their own chapters.
  • Clinical pearl:>/strong> Always rule out medical causes before diagnosing primary anxiety disorder.
"Let's dive deeper into the two disorders you'll see most often..."

05 GAD Diagnostic Criteria

  • The "excessive" and "difficult to control" criteria are what distinguish GAD from normal worry.
  • Muscle tension is often the most specific physical symptom—ask about it specifically.
  • Common misconception: Patients think GAD means being anxious about everything—it's actually about multiple domains but still excessive and uncontrollable.
  • Diagnostic tip: "If you didn't worry, would you still have these symptoms?" helps distinguish primary GAD from secondary anxiety.
"Panic disorder presents differently—it's defined by discrete attacks..."

06 Panic Disorder

  • Key distinction: Anyone can have a panic attack; panic disorder requires recurrent unexpected attacks plus anticipatory anxiety.
  • The medical rule-out checklist: Emphasize importance of cardiac workup—many panic patients present to ED first.
  • Common misconception: Panic attacks aren't 'just psychological'—they involve real physiological changes.
  • Clinical pearl: Panic attacks can occur in ANY anxiety disorder—unexpected attacks define panic disorder.
"Once we've diagnosed, how do we measure severity?..."

07 Screening Tools in Practice

  • GAD-7 is free, validated, and takes 2 minutes—there's no reason not to use it.
  • 5-point change is clinically meaningful—patients may not notice 2-3 point changes.
  • Common misconception: Some providers think screening tools are just for research—no, they're clinical decision-making tools.
  • Emphasize: Use GAD-7 AND PHQ-9 together given high comorbidity.
GAD-7: ≥10 suggests moderate anxiety warranting treatment.
"Understanding screening is enhanced by understanding the underlying neurobiology..."

08 Neurobiology of Anxiety

  • Amygdala "smoke detector" analogy: Helps patients understand why they react before they think.
  • Key teaching point: Anxiety is a brain-based condition, not weakness or character flaw.
  • Clinical relevance: SSRIs take 2-6 weeks because neuroplastic changes are required—this explains delayed onset to patients.
  • Common misconception: That SSRIs work immediately by just 'adding serotonin'—it's more complex than that.
"This biology helps explain why we need to be thoughtful about medication selection..."

09 FDA Black Box Warning

  • Don't let this warning scare you away from treating—just monitor appropriately.
  • Risk is highest in first 1-2 months, then declines with continued treatment.
  • Common misconception: That black box means "don't prescribe"—actually means "monitor closely."
  • Documentation: Document, document, document—this is medicolegal protection.
Context: Untreated depression/anxiety carries higher absolute suicide risk than treatment.
"With monitoring in mind, let's discuss first-line medication options..."

10 First-Line: SSRIs

  • Escitalopram and sertraline are preferred first-line due to tolerability.
  • Start low to minimize activation side effects—patients will stop if they feel worse initially.
  • Common misconception: That patients "just need to push through" activation—actually, titrate slowly.
  • Therapeutic trial: 8-12 weeks at adequate dose before declaring failure.
Key: Fluoxetine's long half-life is advantage for non-adherent patients.
"When SSRIs aren't enough, SNRIs offer additional options..."

11 First-Line: SNRIs

  • Venlafaxine has the broadest anxiety indications of any antidepressant.
  • Discontinuation syndrome warning: Worse than SSRIs—patients need advance warning.
  • Duloxetine is excellent choice when pain comorbidity present—look for this pattern.
  • At low doses, SNRIs act like SSRIs; NE effect kicks in at higher doses.
"Not every patient can tolerate or benefit from first-line agents..."

12 Second-Line Agents

  • Buspirone is often overlooked but effective for GAD specifically—not for panic.
  • Hydroxyzine is excellent PRN option—SUD-safe, no abuse potential.
  • Common misconception: That gabapentin is completely safe—abuse reports are increasing.
  • Pregabalin is first-line in UK/EU but off-label in US—know your local prescribing patterns.
"Which brings us to the most controversial topic..."

13 Benzodiazepine Considerations

  • This is the most controversial slide—be prepared for pushback from audience.
  • Key message: Benzos work great acutely but fail long-term due to tolerance.
  • Common misconception: "Low dose doesn't cause dependence"—actually, tolerance develops at any dose.
  • Alprazolam particularly problematic due to short half-life and interdose withdrawal.
Remember: Benzodiazepine use disorder is iatrogenic in many cases—prevention is key.
"Medications aren't the only effective treatment..."

14 CBT: The Gold Standard

  • Effect size d = 0.80-1.3—this is large effect, comparable to medication.
  • Exposure is the active ingredient—avoid therapists who skip this.
  • Common misconception: That CBT is just "positive thinking"—actually, it's structured skills training.
  • Homework compliance predicts outcome—emphasize this to patients.
"CBT isn't the only evidence-based psychotherapy..."

15 ACT and Other Psychotherapies

  • ACT is evidence-based alternative to CBT—don't dismiss it as "trendy."
  • Some patients prefer ACT's acceptance model over CBT's change focus.
  • Common misconception: That mindfulness-based interventions replace evidence-based care—they're complementary.
  • DBT when personality pathology complicates the picture.
"Let's put this all together in a treatment algorithm..."

16 Treatment Algorithm — GAD

  • Walk through step by step—pause for questions.
  • Mild cases can start with therapy alone—don't reflexively medicate.
  • Severe cases need combined approach and possible psychiatry referral.
  • Common misconception: That medication and therapy are mutually exclusive—they're synergistic.
"Special populations require modification of this algorithm..."

17 Special Populations — Pregnancy

  • Paroxetine is Category D—avoid in pregnancy; switch to sertraline if patient becomes pregnant.
  • Untreated maternal anxiety carries risks too—don't reflexively stop meds.
  • Common misconception: That all SSRIs are unsafe in pregnancy—actually, sertraline has excellent safety data.
  • Neonatal adaptation syndrome is usually mild and self-limited.
"Elderly patients have different risk profiles..."

18 Special Populations — Elderly

  • Beers criteria are clear—benzos should not be used in elderly.
  • Hyponatremia is underappreciated risk—check sodium early with SSRIs.
  • Common misconception: "Low dose benzo is safe in elderly"—actually, any dose increases fall risk.
  • New anxiety in elderly is red flag for cognitive decline—screen cognition.
Principle: "Start low, go slow, but go"—don't undertreat due to age alone.
"Substance use disorders complicate treatment significantly..."

19 Special Populations — SUD Comorbidity

  • Benzo prohibition in active SUD is absolute—no exceptions.
  • Gabapentin was considered safe but abuse reports increasing—use caution.
  • Treat both conditions simultaneously—sequential treatment fails.
  • Common misconception: "Treat the SUD first, then anxiety"—actually, treat both together.
"How do we know if treatment is working?..."

20 Measurement-Based Care

  • Measurement-based care is standard of care—document scores.
  • 5-point change is clinically meaningful—patients may not notice smaller changes.
  • Distinguish response from remission—response = ≥50% improvement; remission = GAD-7 <5.
  • Common misconception: That clinical interview is sufficient—actually, validated measures improve outcomes.
"Documentation protects both patients and providers..."

21 Documentation Requirements

  • Documentation is medicolegal protection—not just busywork.
  • Black box warning discussion must be documented for patients under 25.
  • GAD-7 scores at every visit enable quality metrics.
  • Use templates to ensure consistency and completeness.
"Sometimes we need to refer—here's when..."

22 When to Refer

  • Know your limits—refer when complexity exceeds comfort.
  • Two failed trials = treatment resistance = psychiatry referral.
  • Bipolar comorbidity requires psychiatry—screen for mania history.
  • Build referral network proactively—don't wait until you need it.
"Let's summarize the key points..."

23 Key Takeaways

  • Emphasize treatability—patients often suffer unnecessarily.
  • Remind about remission vs response—don't settle for partial improvement.
  • These are evidence-based, guideline-concordant recommendations.
  • Transition to case discussion.
"Now let's apply this to a challenging case..."

24 Case Discussion

  • Guide discussion to recognize this is NOT treatment-resistant (only 1 adequate trial).
  • Key learning: Distinguish intolerance from inefficacy.
  • Point out venlafaxine never reached therapeutic dose.
  • Emphasize role of CBT in this case—patient needs hope.
"For those wanting to dig deeper, here are key references..."

25 References

  • Thank participants for attention
  • Open for questions
  • Direct to handout materials for quick reference
  • Provide contact information for follow-up

Anticipated Q&A

Can I use SSRIs for panic disorder even though the panic attacks feel so physical?

Yes, absolutely. This is a common misconception. The physical symptoms of panic are driven by the same neurobiological circuits that SSRIs modulate—specifically amygdala hyperactivity and locus coeruleus norepinephrine dysregulation. The physical sensations are real, but they're downstream of central nervous system dysfunction.

SSRIs are first-line for panic disorder because they reduce the sensitivity of the threat detection system. Over 2-6 weeks, patients experience fewer panic attacks, and the attacks that do occur are less intense. The physical symptoms diminish as the underlying neurobiology normalizes. Multiple RCTs show SSRIs reduce panic attack frequency by 70-80%.

Educate patients: "The physical symptoms are real, but they're coming from your brain's alarm system. The medication helps turn down that alarm."

My patient is already on an SSRI for depression — do I need to add anything for anxiety?

Not necessarily. If the patient is on an adequate dose of an SSRI for depression, that same medication is often treating both conditions. SSRIs approved for depression are also first-line for anxiety disorders.

Key questions to ask:

  • What dose are they on? Anxiety often requires higher doses than depression (e.g., sertraline 100-200mg vs. 50-100mg).
  • How long have they been at this dose? Therapeutic effect takes 8-12 weeks.
  • Are they adherent? Partial adherence = partial response.

If they've been on adequate dose for adequate duration with confirmed adherence and still have significant anxiety, consider: (1) dose optimization, (2) augmentation with buspirone or hydroxyzine, (3) adding CBT, or (4) switching to an SNRI if prominent physical symptoms.

The patient is 22yo and anxious about starting an SSRI because of the black box warning — how do I counsel them?

This is a counseling opportunity, not a barrier. Here's the framework:

Acknowledge the concern: "I understand you're worried. That warning exists because in controlled trials, young people starting antidepressants had about twice the rate of suicidal thoughts compared to placebo."

Provide context: "The absolute risk increased from about 2% to 4%. Importantly, untreated depression and anxiety have much higher suicide rates than treated illness. Over time, as symptoms improve, suicide risk decreases below baseline."

Explain monitoring: "Because of this, we'll check in more frequently at first—weeks 1, 2, 4, and 8. You'll have my contact information for emergencies. We also need to involve someone who sees you regularly—parent, roommate, partner—who can tell us if they notice concerning changes."

Document: Written informed consent required for patients under 25.

Is buspirone actually effective or is it just placebo?

Buspirone is genuinely effective—but only for GAD, not panic disorder. It's FDA-approved for GAD based on multiple RCTs showing superiority to placebo and comparable efficacy to benzodiazepines for GAD specifically.

Why it has a reputation problem:

  • Delayed onset (2-4 weeks) leads to early discontinuation
  • Requires TID dosing for optimal effect
  • Ineffective if patient is on benzodiazepines (occupies same receptors)
  • Not effective for panic disorder, so providers try it broadly, see failure, and conclude it's ineffective

Best use: GAD patients who want non-controlled option, have no panic component, and can commit to regular dosing. It's particularly useful in patients with SUD history who can't take controlled substances.

My patient with alcohol use disorder has severe anxiety — what do I prescribe?

This is challenging but common. Absolute rule: No benzodiazepines in active alcohol use disorder—high abuse liability, dangerous with alcohol, and can trigger relapse.

Medication options:

  • SSRIs: Sertraline or escitalopram first-line. Can treat both depression and anxiety.
  • Buspirone: Non-controlled; good for GAD.
  • Hydroxyzine: PRN option; no controlled status.
  • Gabapentin: Use with caution—emerging abuse reports, but some evidence for alcohol withdrawal and anxiety.

Key principle: Treat anxiety AND substance use simultaneously. Sequential treatment ("treat the alcohol first") has poorer outcomes. Consider referral to addiction psychiatry if available.

How long do patients need to stay on SSRIs for anxiety?